Additionally, intratumoral and peripheral CD4+FOXP3−PD-1hi nonconventional Tregs in NSCLC as well as melanoma patients were reported as prognostic biomarkers for anti-PD-1 and anti-CTLA-4 therapies31. The gene discussed is CTLA4; the disease is melanoma.